advisory panels

FDA Advisory Committee Raises Objections to Pfizer and Eli Lilly’s Tanezumab
FDA Advisory Committee Raises Objections to Pfizer and Eli Lilly’s Tanezumab
BioSpace
FDA
advisory panels
Pfizer
Eli Lilly
tanezumab
osteoarthritis
Flag link:
Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried
Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried
Endpoints
Pfizer
Eli Lilly
tanezumab
FDA
advisory panels
osteoarthritis
Flag link:
FDA arranges Feb. 26 AdComm to discuss J&J COVID-19 vaccine EUA
FDA arranges Feb. 26 AdComm to discuss J&J COVID-19 vaccine EUA
Fierce Biotech
FDA
JNJ
advisory panels
vaccines
COVID-19
Emergency Use Authorization
Flag link:
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Biopharma Dive
Biogen
aducanumab
FDA
advisory panels
Alzheimer's disease
Flag link:
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Stat
Biogen
aducanumab
Alzheimer's disease
FDA
advisory panels
Flag link:
Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel
Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel
Investors Business Daily
Biogen
aducanumab
Alzheimer's disease
FDA
analysts
advisory panels
mock advisory panels
Flag link:
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
Xconomy
Alkermes
FDA
advisory panels
ALKS 3831
schizophrenia
bipolar disorder
Flag link:
FDA Panel Votes 8-7 in Favor of Mallinckrodt's HRS-1 Drug
FDA Panel Votes 8-7 in Favor of Mallinckrodt's HRS-1 Drug
BioSpace
Mallinckrodt
FDA
terlipressin
HRS-1
advisory panels
Flag link:
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
MedCity News
belantamab mafodotin
GSK
Multiple Myeloma
FDA
advisory panels
Flag link:
FDA moots virtual AdComms but delays GSK, Intercept meetings
FDA moots virtual AdComms but delays GSK, Intercept meetings
Fierce Biotech
FDA
advisory panels
GSK
Intercept Pharma
Flag link:
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Pharmaforum
Eli Lilly
Cyramza
non-small cell lung cancer
FDA
advisory panels
Flag link:
FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality
FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality
Motley Fool
GSK
FDA
advisory panels
COPD
Trelegy Ellipta
Flag link:
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
advisory panels
Flag link:
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
Endpoints
FDA
advisory panels
Horizon Therapeutics
thyroid eye disease
teprotumumab
Flag link:
What's Next for Amarin's Stock?
What's Next for Amarin's Stock?
Motley Fool
Amarin
Vascepa
FDA
pharma stocks
advisory panels
Flag link:
The future of Vascepa sales, and Amarin, could hinge on next week's panel
The future of Vascepa sales, and Amarin, could hinge on next week's panel
EP Vantage
Amarin
Vascepa
FDA
advisory panels
M&A
Flag link:
FDA Ad Com thumbs down on full Makena approval
FDA Ad Com thumbs down on full Makena approval
Seeking Alpha
Makena
preterm birth
Amag Pharmaceuticals
FDA
advisory panels
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
Fierce Pharma
GSK
FDA
advisory panels
OTC
Flag link:

Pages